Skip to main content
Publications
Quinn KL, Abdel-Qadir H, Barrett K, Bartsch E, Beaman A, Biering-Sorensen T, Colacci M, Cressman A, Detsky A, Gosset A, Lassen MH, Kandel C, Khaykin Y, Lapointe-Shaw L, Lovblom E, MacFadden DR, Perkins B, Rothman KJ, Skaarup KG, Stall N, Tang T, Yarnell C, Zipursky J, Warkentin MT, Fralick M, COVID-ACE Group. Variation in the risk of death due to COVID-19: an international multicenter cohort study of hospitalized adults. J Hosp Med. 2022 Oct 1;17(10):739-802. doi: 10.1002/jhm.12946
Cheol Lee J, Hung JY, Kim YC, Chang GC, Soo Yoo S, Yang SH, Davis KL, Nagar SP, Taylor A, Yong Lee S, Shih JY. Real-world treatment patterns in patients with EGFR mutation-positive NSCLC receiving a first line, first- or second-generation EGFR tyrosine kinase inhibitor in South Korea and Taiwan. Asian Pac J Cancer Bio. 2021 May 20;6(2). doi: 10.31557/APJCB.2021.6.2.123-132
Paquette M, Franca LR, Teutsch C, Diener HC, Lu S, Dubner SJ, Ma CS, Rothman KJ, Zint K, Halperin JL, Olshansky B, Huisman MV, Lip GYH, Nieuwlaat R. Dabigatran persistence and outcomes following discontinuation in atrial fibrillation patients from the GLORIA-AF registry. Am J Cardiol. 2020 Feb 1;125(3):383-91. doi: 10.1016/j.amjcard.2019.10.047
Ribera A, Ferreira-Gonzalez I, Marsal JR, Cascant P, Permanyer-Miralda G, Abdul-Jawad O, Inigo-Garcia LA, Guarinos-Oltra J, Cequier A, Goicolea-Guemez L, Garcia-Del-Blanco B, Marti G, Garcia-Dorado D. Prognostic value of an abnormal ankle-brachial index in patients receiving drug-eluting stents. Am J Cardiol. 2011 Nov 1;108(9):1225-31. doi: 10.1016/j.amjcard.2011.06.036